


WHAT IS CLAIMED IS:

1. Use of Compound 1 having the formula:




Compound 1

in the manufacture of a medicament for the treatment of cholangiocarcinoma, and wherein the medicament is to be administered to a patient a daily dose of about 5 mg to about 20 mg.

2. The use of claim 1, wherein the cholangiocarcinoma is advanced or metastatic cholangiocarcinoma.
3. The use of claim 1, wherein the cholangiocarcinoma is surgically unresectable.
4. The use of claim 1, wherein the cholangiocarcinoma is intrahepatic.
5. The use of claim 1, wherein the cholangiocarcinoma is extrahepatic.
6. The use of claim 1, wherein the cholangiocarcinoma is hilar or perihilar.
7. The use of claim 1, wherein the cholangiocarcinoma is distal extrahepatic.
8. The use of claim 1, wherein the cholangiocarcinoma is characterized by FGF/FGFR genetically altered tumors.
9. The use of claim 8, wherein the tumor exhibits FGFR2 translocations.

10. The use of claim 9, wherein the FGFR2 translocation is selected from the group consisting of FGFR2-BICC1, FGFR2-AHCYL1, FGFR2-MACF1, and FGFR2 intron 17 rearrangement.
11. The use of claim 8, wherein the tumor exhibits FGF/FGFR alterations other than FGFR2 translocations.
12. The use of claim 1, wherein the cholangiocarcinoma does not exhibit FGF/FGFR genetically altered tumors.
13. The use of claim 1, wherein the patient has failed at least one previous treatment.
14. The use of claim 13, wherein the previous treatment is surgery or radiation therapy.
15. The use of claim 1, wherein the patient has a history of hepatitis.
16. The use of claim 15, wherein the hepatitis is chronic hepatitis B or hepatitis C.
17. The use of claim 1, wherein the medicament is to be administered in a daily dose of about 10 mg to about 15 mg.
18. The use of claim 1, wherein the medicament is to be administered in a daily dose of about 13.5 mg.
19. The use of claim 1, wherein the medicament is to be administered as a tablet.
20. The use of claim 1, wherein the medicament is to be administered in a daily dose of about 9 mg.

21. Use of Compound 1 having the formula:



Compound 1,

in the manufacture of a medicament for the treatment of cholangiocarcinoma, wherein the medicament is to be administered once daily as a tablet, and wherein the tablet comprises about 0.5 to about 10 mg of Compound 1.

22. The use of claim 21, wherein the tablet comprises about 0.5 mg to about 5 mg of Compound 1.

23. The use of claim 21, wherein the tablet comprises about 9 mg of Compound 1.

24. The use of claim 21, wherein the tablet comprises about 4.5 mg of Compound 1.

25. The use of claim 21, wherein the cholangiocarcinoma is advanced or metastatic cholangiocarcinoma.

26. The use of claim 21, wherein the cholangiocarcinoma is surgically unresectable.


27. The use of claim 21, wherein the cholangiocarcinoma is intrahepatic.

28. The use of claim 21, wherein the cholangiocarcinoma is extrahepatic.

29. The use of claim 21, wherein the cholangiocarcinoma is hilar or perihilar.

30. The use of claim 21, wherein the cholangiocarcinoma is distal extrahepatic.

31. The use of claim 21, wherein the cholangiocarcinoma is characterized by FGF/FGFR genetically altered tumors.
32. The use of claim 31, wherein the tumor exhibits FGFR2 translocations.
33. The use of claim 32, wherein the FGFR2 translocation is selected from the group consisting of FGFR2-BICC1, FGFR2-AHCYL1, FGFR2-MACF1, and FGFR2 intron 17 rearrangement.
34. The use of claim 31, wherein the tumor exhibits FGF/FGFR alterations other than FGFR2 translocations.
35. The use of claim 21, wherein the cholangiocarcinoma does not exhibit FGF/FGFR genetically altered tumors.
36. The use of claim 21, wherein the patient has failed at least one previous treatment.
37. The use of claim 36, wherein the previous treatment is surgery or radiation therapy.
38. Use of Compound 1 having the formula:



Compound 1,

in the manufacture of a medicament for the treatment of cholangiocarcinoma, wherein the medicament is to be administered to a patient in a 21-day dosing regimen, wherein the 21-day dosing regimen comprises:

- (a) a first period wherein the medicament is to be administered once daily for 14 days;
and
(b) a second period wherein the medicament is not to be administered for 7 days.

39. The use of claim 38, wherein the medicament is to be administered in a daily dose of about 5 mg to about 20 mg during the first period.
40. The use of claim 38, wherein the medicament is to be administered in a daily dose of about 10 mg to about 15 mg during the first period.
41. The use of claim 38, wherein the medicament is to be administered in a daily dose of about 13.5 mg during the first period.
42. The used of claim 38, wherein the medicament is to be administered in a daily dose of about 9 mg during the first period.
43. The use of claim 38, wherein the medicament is to be administered as a tablet during the first period.
44. The use of claim 43, wherein the tablet comprises about 0.5 mg to about 10 mg of Compound 1.
45. The use of claim 43, wherein the tablet comprises about 0.5 mg to about 5 mg of Compound 1.
46. The use of claim 43, wherein the tablet comprises about 9 mg of Compound 1
47. The use of claim 43, wherein the tablet comprises about 4.5 mg of Compound 1.
48. The use of claim 38, wherein the cholangiocarcinoma is advanced or metastatic cholangiocarcinoma.
49. The use of claim 38, wherein the cholangiocarcinoma is surgically unresectable.

50. The use of claim 38, wherein the cholangiocarcinoma is intrahepatic.
51. The use of claim 38, wherein the cholangiocarcinoma is extrahepatic.
52. The use of claim 38, wherein the cholangiocarcinoma is hilar or perihilar.
53. The use of claim 38, wherein the cholangiocarcinoma is distal extrahepatic.
54. The use of claim 38, wherein the cholangiocarcinoma is characterized by FGF/FGFR genetically altered tumors.
55. The use of claim 54, wherein the tumor exhibits FGFR2 translocations.
56. The use of claim 55, wherein the FGFR2 translocation is selected from the group consisting of FGFR2-BICC1, FGFR2-AHCYL1, FGFR2-MACF1, and FGFR2 intron 17 rearrangement.
57. The use of claim 54, wherein the tumor exhibits FGF/FGFR alterations other than FGFR2 translocations.
58. The use of claim 38, wherein the cholangiocarcinoma does not exhibit FGF/FGFR genetically altered tumors.
59. The use of claim 38, wherein the patient has failed at least one previous treatment.
60. The use of claim 59, wherein the previous treatment is surgery or radiation therapy.